Policy UpdatesMedicare AdvantageDecember 6, 2024

Clinical Criteria updates

Effective January 9, 2025

Summary: On September 20, 2024 and October 2, 2024 the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.

Please see the explanation/definition for each category of Clinical Criteria below:

  • New: newly published criteria
  • Revised: addition or removal of medical necessity requirements, new document number
  • Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Please note:

  • The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
  • This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective date

Clinical Criteria number

Clinical Criteria title

New or revised

January 9, 2025

*CC-0267

Ebglyss (lebrikizumab-lbkz)

New

January 9, 2025

*CC-0268

Lymphir (denileukin diftitox-cxdl)

New

January 9, 2025

*CC-0269

Nemluvio (nemolizumab-ilto)

New

January 9, 2025

*CC-0270

Niktimvo (axatilmab-csfr)

New

January 9, 2025

*CC-0271

Tecelra (afamitresgene autoleucel)

New

January 9, 2025

*CC-0012

Brineura (cerliponase alfa)

Revised

January 9, 2025

*CC-0250

Veopoz (pozelimab-bbfg)

Revised

January 9, 2025

*CC-0072

Vascular Endothelial Growth Factor (VEGF) Inhibitors

Revised

January 9, 2025

*CC-0029

Dupixent (dupilumab)

Revised

January 9, 2025

CC-0201

Rybrevant (amivantamab-ymjw)

Revised

January 9, 2025

CC-0130

Imfinzi (durvalumab)

Revised

January 9, 2025

*CC-0002

Colony Stimulating Factor Agents

Revised

January 9, 2025

CC-0050

Monoclonal Antibodies to Interleukin-23

Revised

January 9, 2025

*CC-0011

Ocrevus (ocrelizumab)/Ocrevus Zunovo (ocrelizumab/hyaluronidase-ocsq)

Revised

Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company, and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

CABC-CR-071473-24-CPN71236

PUBLICATIONS: January 2025 Provider Newsletter